Subscribe To
LBPS / 4D pharma sees early success as phase I/II cancer trial hits its efficacy target early
LBPS News
By Proactive Investors
November 16, 2022
4D pharma says phase II IBS results published in scientific journal
4D pharma PLC said results from a phase II evaluation of its key irritable bowel treatment LBP Blautix have appeared in a peer-reviewed scientific pub more_horizontal
By Proactive Investors
May 27, 2022
4D Pharma outlines phase II plans for promising cancer drug candidate
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) will deliver what's called a ‘trial in progress' poster at a world-leading cancer conference outlining the pla more_horizontal
By Proactive Investors
May 17, 2022
4D pharma conference poster underlines safety and potential efficacy of asthma drug candidate
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it will present an update from the phase I/II trial of its putative asthma treatment at an industry confere more_horizontal
By Proactive Investors
April 1, 2022
4D Pharma has a busy year ahead after a successful 12 months of clinical research
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has some significant milestones upcoming this year after a successful 12 months of developing assets that target more_horizontal
By Proactive Investors
March 23, 2022
4D Pharma PLC soars after meeting endpoint early
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) jumped 27% in London trading after the company hit its primary efficacy target in a phase I/II trail of one of i more_horizontal
By Benzinga
March 23, 2022
4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinoma
4D pharma plc (NASDAQ: LBPS) has announced interim results from Phase 1/2 study evaluating the combination of MRx0518 and Merck & Co Inc's (NYSE: more_horizontal
By Proactive Investors
March 23, 2022
4D pharma sees early success as phase I/II cancer trial hits its efficacy target early
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it had hit its primary efficacy target in a phase I/II trial of one of its lead assets in kidney cancer. MR more_horizontal
By Proactive Investors
February 22, 2022
4D pharma receives US regulatory green light for phase I trial of its Parkinson's disease candidates
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has received the green light for a first-in-human trial of its Parkinson's disease candidates in the US. This is more_horizontal